I'm glad Mr Red that you have made some good coin. Sorry to see you're leaving now when I think the present steady low is a good entry point, or top us as I have done today. But as you say, you'll be back if it takes off again. See you then.
For other readers, I rarely day trade or trade the small shifting swings. I prefer to buy the lows when I like a stock and ride it out to eventual victory. Horses for courses.
Anyway, as the weekend is looming and we've been here a short while now with Biotron's new impetus, not withstanding those long termers, and the trading week is almost past, some hopefuls will by beginning to worry about their overnight sensation that hasn't arrived. Maybe they're beginning to believe that it won't. Maybe, like Mr. Red, they'll quit the game with their present winnings, or losses, whatever the case.
Being Friday afternoon, lets play a game to set the tone for the weekend. I suggest the future game. It's easy to play. Pick your future and describe it. But there is a strict rule. It must be practical. It must be demonstrable within reason. It can't rely solely on hopes. There must be proof.
So for example, if your future play is to win the lotto tonight, your game plan can't be based solely on your desire to win. Oh, I hope I win the lotto tonight. Sorry, you lose.
No, if you were going to play the future game with lotto, you'd require an evidence based game plan that would point towards your forthcoming lotto win, like the one below. I won lotto four times in January, so my chances tonight are pretty good.
Batmansdaughter's January lotto wins. (It helps when your daddy has a secret formula. Where else does he get all his funds to support his work).
But my future game play is not lotto. It's Biotron. I'll go first because because I'm holding the dice. Here's my evidence based game plan that Biotron will soon be a household name, globally.
Biotron has a library of compounds that quickly whip up to be antivirals against common viruses: HIV; Hep's; Coronas etc
Biotron's compounds have so far within the confines of their testing, have proven very successful.
There is every chance that these compounds will eventually prove to be successful at the commercial level because they may prove to be far better than present antivirals attempting to achieve the same goals. There success will be based on their new mode of killer action.
More immediately, there happens to be an outbreak of a pesky deadly virus that is out of hand and no one has any idea how to stop it.
Biotron just happens to have some compounds that probably are suitable for the occasion, and co-incidentally just filed some US Patent applications that demonstrate this point.
Biotron therefore got to work almost immediately on the project by hiring some labs that have access to the pesky virus to try their compounds.
The results of these trials are forthcoming and likely to be successful, because the pesky virus isn't really that different to the ones they've experimented with previously.
Biotron will be successful dealing with this pesky virus and will become a household name for their efforts.
Batmansdaughter wins her play.
Your turn.
BD, I find most what you post here and DT forums quite refreshing in the sarcasm sense, similar traits to another of my HC favourites @IDontLikeWorking, especially enjoy the linked with key word to facts.
Though I must say Daddy’s winning formula needs a bit of an update, $9 in did go quite far 1939 but my dear gal, 81 years have passed and I am afraid that value stretch has gone slack. The caped crusader first appeared on May 1st, 1939 Detective Comics #27. A recalibration may be in order for the secret formula.
Your evidence base game has started with statements, all I pretty much agree with but may I be of some assistance in filling the file, as you have done in previous posts and I understand it can be quite a bore with a couple of hundred rubbish post’s daily on the BIT slinging fest pages.
How advance are Biotron in investigating Corana, thought someone on this thread would never ask, @J8 would say, “Surely you Jest”
ANTIVIRAL COMPOUNDS AND METHODS
Publication number: 20190389816
Abstract: The invention relates to compounds having antiviral and methods utilizing the compounds to treat viral infections.
Type: Application
Filed: August 29, 2019
Publication date: December 26, 2019
Applicant: Biotron Limited
A further well-known family of pathogenic viruses are the Coronaviruses. Coronaviruses (Order Nidovirales, family Coronaviridae, Genus Coronavirus) are enveloped positive-stranded RNA viruses that bud from the endoplasmic reticulum-Golgi intermediate compartment or the cis-Golgi network (Fischer, Stegen et al. 1998; Maeda, Maeda et al. 1999; Corse and Machamer 2000; Maeda, Repass et al. 2001; Kuo and Masters 2003)
Coronaviruses infect humans and animals and it is thought that there could be a coronavirus that infects every animal. The two human coronaviruses, 229E and OC43, are known to be the major causes of the common cold and can occasionally cause pneumonia in older adults, neonates, or immunocompromised patients (Peiris, Lai et al. 2003).
Severe acute respiratory syndrome (SARS) is caused by a newly identified virus. SARS is a respiratory illness that has recently been reported in Asia, North America, and Europe (Peiris, Lai et al. 2003). The causative agent of SARS was identified as a coronavirus. (Drosten, Gunther et al. 2003; Ksiazek, Erdman et al. 2003; Peiris, Lai et al. 2003).
The World Health Organization reports that the cumulative number of reported probable cases of SARS from 1 Nov. 2002 to the 11 Jul. 2003 is 8,437 with 813 deaths, nearly a 10% death rate. It is believed that SARS will not be eradicated, but will cause seasonal epidemics like the cold or influenza viruses(Vogel 2003).
To improve the prospect of treating and preventing viral infections, there is an on-going need to identify molecules capable of inhibiting various aspects of the viral life cycle.
It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.
The SARS virus encodes an E protein which is shown for the first time, by the present inventors, to act as an ion channel. As similar E proteins are present in other coronaviruses, the compounds, compositions and methods of the present invention would have utility in the inhibition and/or treatment of infections by other coronaviruses.
Further support of data in this area in our compound library.
Biotron executes agreement with NIAID for evaluation of Zika candidates back in 2016.
As previously announced, Biotron has been screening its library of small molecule compounds against Zika virus. Previously, two compounds with anti-Zika activity were identified.
Ongoing testing in cell culture assays has identified additional compounds that are able to inhibit Zika virus activity, several of which have greater potency against the virus than the first two compounds.
Recently, the Company executed an agreement under which the Company will utilise the nonclinical and pre-clinical services program offered by United State’s National Institute of Allergy and Infectious Diseases (NIAID).
Safety data and toxicology set - from the radio interview, ready to act fast in this space.
Answer to the impatience “when will be the next update” 2-6 weeks screening process pending on the hits in the Petrie.
Thursday 6th of February was the last announce Biotron to Test its Compounds Against Coronavirus which leaves at best 20th of Feb, so I would not bet on Monday Ann and market has factored the testing range with it pulled back.
Timeline going forward is starting to fill up with key dates.
8th-11th of March The Annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. http://www.croiconference.org/
This has involved detailed post-trial analyses of trial samples. These analyses now provide key information on how BIT225 induces the significant beneficial immunological changes observed in the completed Phase 2 clinical trialand form the basis of the paper to be presented at CROI.
Nicely dropped at the end of Ann back in December 2019
The Company is focused on achieving a commercial outcome for its promising antiviral programs whilst continuing to progress its clinical HIV-1 program to prepare for more advanced clinical trials, including Phase 3 studies.
To this end, Biotron has engaged an international contract research organisation to complete chronic toxicology studies of BIT225 to enable the long-term human dosing required for this next stage of clinical development.
Six month long dosing range due to be completed around June/ July. This was my initial exit plan target but X-mas does come more than once a year, pending on your belief system.
Only concern again from radio interview, C/O has two year of funding left in the coffers and the director rights issue vesting date in 31/01/2021 is somewhat a concern, that a deal may take a little longer then next week.
Though it stats for MM performance options that any commercial deal 5 million options are available at 25 cent strike price.
Exercisable at any time after the vesting date before the expiry date each to acquire 1 fully paid ordinary share ranking pari passu with existing shares and, for Tranche 1, subject to the COMPLETION OF A COMMERCIALISATION TRANSACTION(As determine by Plan Committee)
No mention of minimum deal amount, who is to say the C/O sells 5 compounds for 50 million, after positive Petrie results. No link to HIV deal for #BIT-225.
Anyway BD, your face looks familiar but no doubt it’s the saturation of the Bruce factor resemblance.
DYOR - ONLY MY OPINION - GLTAH
BIT Price at posting:
11.5¢ Sentiment: Hold Disclosure: Held
(20min delay)
